GLEEVEC vs OFEV

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated October 4, 2026·How we rate

Possible drug interaction. GLEEVEC and OFEV are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	GLEEVEC	OFEV
Rating	70/100	72/100
Pharmacy pays	~$25.80 /30	~$485.32 /30
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	NINTEDANIB ESYLATE
Manufacturer	Novartis	Boehringer Ingelheim
Dosage forms	Tablet	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Idiopathic Pulmonary Fibrosis

gleevec ofev

Rating

70/100

72/100

Pharmacy pays

~$25.80 /30

~$485.32 /30

Type

Active ingredient

IMATINIB MESYLATE

NINTEDANIB ESYLATE

Manufacturer

Novartis

Boehringer Ingelheim

Dosage forms

Tablet

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Idiopathic Pulmonary Fibrosis

Frequently asked questions

Which is better-rated, Gleevec or Ofev?

By our independent rating, Ofev scores higher — 3.6 vs 3.5 out of 5 for Gleevec. Ratings are based on FDA regulatory (recall-safety) data.

Which is cheaper, Gleevec or Ofev?

Gleevec costs pharmacies less to acquire — about $25.80 vs $485.32 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Gleevec and Ofev?

Gleevec contains Imatinib Mesylate, while Ofev contains Nintedanib Esylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.